Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GM-CSF + lenalidomide + glofitamab
- Development stage
- Preclinical
- Lead developer
- Genentech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral, Intravenous
01
Overview
This is a combination therapy consisting of GM-CSF (granulocyte-macrophage colony-stimulating factor), lenalidomide, and glofitamab. GM-CSF is a cytokine that stimulates the production and function of granulocytes and macrophages. Lenalidomide is an immunomodulatory drug with antineoplastic and anti-angiogenic properties. Glofitamab is a T-cell engaging bispecific antibody targeting CD20 on B cells and CD3 on T cells. According to the search results, glofitamab is administered starting on the 7th day after the end of radiotherapy in some protocols, with GM-CSF administered in conjunction with the therapy.
- Other names
- GM-CSF + lenalidomide + glofitamabLarge Fraction RT + GM-CSF + Lenalidomide + Glofitamab
02
Targets
CRBN (Cereblon)CD20 (B-lymphocyte antigen CD20)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on GM-CSF + lenalidomide + glofitamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GM-CSF + lenalidomide + glofitamab.